|
|
|
Insider
Information: |
Goeddel David V |
Relationship: |
10% Owner |
City: |
So. San Francisco |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
9 |
|
Direct
Shares |
21,008,913 |
|
Indirect Shares
|
32,725,451 |
|
|
Direct
Value |
$109,933,645 |
|
|
Indirect Value
|
$151,903,676 |
|
|
Total
Shares |
53,734,364 |
|
|
Total
Value |
$261,837,321 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
63
|
4
|
Stock
price went up :
|
24
|
1
|
Stock
price went down : |
39
|
3
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
-0.2%
|
-73.3%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Immune Design Corp. |
IMDZ |
10% Owner |
2016-09-20 |
3,961,942 |
2014-07-29 |
0 |
Premium* |
|
Gritstone Oncology, Inc. |
GRTS |
Managing Partner |
2018-10-02 |
3,102,934 |
2018-10-02 |
0 |
Premium* |
|
Ngm Biopharmaceuticals Inc |
NGM |
Director, 10% Owner |
2024-04-05 |
0 |
2024-04-05 |
1,000 |
Premium* |
|
Rapt Therapeutics, Inc. |
RAPT |
Managing Partner, 10% ... |
2020-09-22 |
5,630,497 |
2019-11-04 |
195,401 |
Premium* |
|
Oric Pharmaceuticals, Inc. |
ORIC |
Managing Partner, 10% ... |
2020-04-28 |
4,768,181 |
|
0 |
Premium* |
|
Revolution Medicines, Inc. |
RVMD |
10% Owner |
2020-11-16 |
2,151,026 |
2020-11-16 |
3,799,202 |
Premium* |
|
Nurix Therapeutics, Inc. |
NRIX |
10% Owner |
2021-05-05 |
1,394,333 |
2021-05-05 |
1,420,954 |
Premium* |
|
Tenaya Therapeutics, Inc. |
TNYA |
|
2021-08-03 |
0 |
2024-02-12 |
22,999,565 |
Premium* |
|
Effector Therapeutics Ord Shs |
EFTR |
10% Owner |
|
0 |
2021-08-25 |
4,309,329 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
145 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 3 of 6
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2023-01-31 |
4 |
B |
$5.00 |
$883,403 |
I/I |
176,730 |
927,231 |
2.25 |
% |
|
IMDZ |
Immune Design Corp. |
10% Owner |
|
2016-09-20 |
4 |
B |
$6.25 |
$5,000,000 |
D/D |
800,000 |
3,961,942 |
2.45 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
10% Owner |
|
2019-10-09 |
4 |
B |
$10.26 |
$181,848 |
I/I |
17,724 |
16,374,631 |
1.5 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-10-16 |
4 |
B |
$10.26 |
$358,074 |
I/I |
34,900 |
16,513,079 |
2.25 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-10-15 |
4 |
B |
$10.31 |
$342,292 |
I/I |
33,200 |
16,478,179 |
2.25 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-10-14 |
4 |
B |
$10.36 |
$361,564 |
I/I |
34,900 |
16,444,979 |
2.25 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
10% Owner |
|
2019-10-10 |
4 |
B |
$10.50 |
$186,102 |
I/I |
17,724 |
16,392,355 |
1.5 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
10% Owner |
|
2019-10-11 |
4 |
B |
$10.57 |
$187,343 |
I/I |
17,724 |
16,410,079 |
1.5 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-10-17 |
4 |
B |
$10.62 |
$72,407 |
I/I |
6,818 |
16,519,897 |
2.25 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-05-09 |
4 |
B |
$10.79 |
$897,699 |
I/I |
83,175 |
30,786 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-05-11 |
4 |
B |
$11.23 |
$935,354 |
I/I |
83,175 |
34,563 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-10-18 |
4 |
B |
$11.29 |
$392,000 |
I/I |
34,721 |
16,554,618 |
2.25 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-05-10 |
4 |
B |
$11.36 |
$355,283 |
I/I |
31,265 |
31,818 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2020-03-19 |
4 |
B |
$11.59 |
$1,720,698 |
I/I |
148,464 |
16,950,815 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-05-12 |
4 |
B |
$11.62 |
$966,678 |
I/I |
83,175 |
37,308 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2020-03-23 |
4 |
B |
$11.63 |
$1,981,601 |
I/I |
170,387 |
17,264,284 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2020-03-20 |
4 |
B |
$11.77 |
$1,684,075 |
I/I |
143,082 |
17,093,897 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-10-23 |
4 |
B |
$11.86 |
$24,752 |
I/I |
2,087 |
16,602,405 |
2.17 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-10-21 |
4 |
B |
$11.94 |
$518,196 |
I/I |
43,400 |
16,598,018 |
2.25 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-11-04 |
4 |
B |
$11.99 |
$100,824 |
I/I |
8,409 |
16,610,814 |
2.25 |
- |
|
IMDZ |
Immune Design Corp. |
10% Owner |
|
2014-07-29 |
4 |
B |
$12.00 |
$4,788,192 |
D/D |
399,016 |
3,161,942 |
2.45 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-10-22 |
4 |
B |
$12.00 |
$27,600 |
I/I |
2,300 |
16,600,318 |
2.25 |
- |
|
RAPT |
Rapt Therapeutics, Inc. |
Director |
|
2019-11-04 |
4 |
B |
$12.00 |
$7,500,000 |
I/I |
625,000 |
4,982,333 |
2.25 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-11-11 |
4 |
B |
$12.00 |
$180 |
I/I |
15 |
16,610,829 |
2.17 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2020-03-24 |
4 |
B |
$12.22 |
$1,568,767 |
I/I |
128,377 |
17,392,661 |
2.25 |
% |
|
145 Records found
|
|
Page 3 of 6 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|